VIEWPOINTS


Viewpoints are a collection of news and opinion articles that capture key research developments and important issues in the field of oncology.


Can Targeting Inflammatory Microenvironments Improve Cancer Therapy Effectiveness?

Can Targeting Inflammatory Microenvironments Improve Cancer Therapy Effectiveness?

Targeting tumor and extracellular LPA could help deny tumors their inflammatory habitat and improve the efficacy of radiotherapy, chemotherapy, and possibly immunotherapies.

The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma

The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma

It is not always clear whether patients who discontinue anti-PD-1 and -CTLA-4 therapy should re-initiate treatment after adverse events are resolved.

Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance

Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance

The results of this study support previous findings that psychological distress is associated with an increased risk of mortality among patients with lung cancer.

New Data Suggest Potential Role for c-MET Inhibition in EGFR TKI-Resistant NSCLC

New Data Suggest Potential Role for c-MET Inhibition in EGFR TKI-Resistant NSCLC

c-MET, although rarer than T790M, may be a promising therapeutic target for patients who progress on EGFR TKI therapy.

Durvalumab: Previous Findings and Current Research

Durvalumab: Previous Findings and Current Research

Several ongoing clinical trials are also evaluating durvalumab as a single agent or in combination with other therapies, such as tremelimumab, and as a first-line therapy.

Will Maintenance Lenalidomide Become A Standard for Relapsed CLL?

Will Maintenance Lenalidomide Become A Standard for Relapsed CLL?

CONTINUUM suggests that maintenance therapy with lenalidomide is an effective way for prolonging progression-free survival without affecting potential subsequent lines of therapy.

Myeloma: Proteasome Inhibitors and IMiDs May Increase Risk of Cardiovascular Complications

Myeloma: Proteasome Inhibitors and IMiDs May Increase Risk of Cardiovascular Complications

Patients with underlying cardiovascular disease and/or baseline hypertension and coronary artery disease may be at a higher risk.

Chemotherapy for HER2-negative Metastatic Breast Cancer

Chemotherapy for HER2-negative Metastatic Breast Cancer

The future of chemotherapy-based options for patients with HER2-negative MBC is evolving, with emerging agents and combinations being studied in ongoing clinical trials.

Notch Inhibition: A Way Forward for Triple-negative Breast Cancer?

Notch Inhibition: A Way Forward for Triple-negative Breast Cancer?

Since the discovery of the notch pathway 25 years ago, several studies have found a link between different Notch receptors and specific forms of breast cancer, including triple-negative.

NSCLC: Liquid Biopsy May Predict Patient Response to Immune Checkpoint Inhibition

NSCLC: Liquid Biopsy May Predict Patient Response to Immune Checkpoint Inhibition

Liquid biopsy can be useful in cases where small bronchial biopsies contain a low number of tumor cells, and the repeatability of liquid biopsies can offer new approaches for monitoring patients treated with immunotherapy.

Success of Adoptive Cell Therapy in ALL Could Be Applied to Myeloma

Success of Adoptive Cell Therapy in ALL Could Be Applied to Myeloma

In the treatment of myeloma, researchers are using therapies engineered to target a protein on myeloma cells called B cell maturation antigen.

PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma

PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma

Researchers found that cells resistant to both BRAF inhibition and combination inhibition were sensitive to PAK inhibition, and further that PAK inhibition slowed cell-cycle progression.

Adjuvant Therapy in Renal Cell Carcinoma: Still Riddled With Unknowns

Adjuvant Therapy in Renal Cell Carcinoma: Still Riddled With Unknowns

About one-third of patients will experience disease recurrence after undergoing nephrectomy, and clinical trials exploring the use of adjuvant therapy in these patients produce conflicting results.

Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma

Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma

Ongoing trials, including those that combine immunotherapy with BRAF inhibitors or a triple combination of an anti-PD-1 antibody with BRAF and MEK inhibitors, may provide more options to patients.

Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?

Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?

While renal cell carcinoma treatment continue to improve, it's unclear whether pazopanib should be used in the adjuvant setting.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters